SCHEMBL26631081

SCHEMBL26631081

CCc1nc(OC2CCC3(CC2)CN(C(=O)C2CC(C)(O)C2)C3)ccc1C(F)F

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CHRM4 P08173 3/20 0.34
▸ CHRM1 P11229 3/20 0.34
▸ CHRM2 P08172 2/20 0.34
▸ ABHD6 Q9BV23 3/20 0.33
▸ LOXL2 Q9Y4K0 2/20 0.32
▸ DGAT2 Q96PD7 1/20 0.32
▸ ACACB O00763 5/20 0.31
▸ MGLL Q99685 2/20 0.31
▸ FAAH O00519 1/20 0.31
▸ JAK2 O60674 3/20 0.31
▸ JAK1 P23458 3/20 0.31
▸ TYK2 P29597 3/20 0.31
▸ JAK3 P52333 2/20 0.31
▸ LIPE Q05469 1/20 0.30
▸ CNR2 P34972 1/20 0.30
▸ CHRM5 P08912 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26739483 1.00 CHRM4 (0.34) CHRM4CHRM1CHRM2ABHD6LOXL2
SCHEMBL29426752 1.00 CHRM4 (0.34) CHRM4CHRM1CHRM2ABHD6LOXL2
SCHEMBL26750412 0.89 CHRM2 (0.33) CHRM4CHRM1CHRM2DGAT2ACACB
SCHEMBL26739475 0.88 ABHD6 (0.35) CHRM4CHRM1CHRM2ABHD6LOXL2
SCHEMBL29426770 0.88 ABHD6 (0.35) CHRM4CHRM1CHRM2ABHD6LOXL2
SCHEMBL26631154 0.88 ABHD6 (0.35) CHRM4CHRM1CHRM2ABHD6LOXL2
SCHEMBL26739479 0.87 LIPE (0.33) CHRM4CHRM1CHRM2ABHD6LOXL2
SCHEMBL26631104 0.87 LIPE (0.33) CHRM4CHRM1CHRM2ABHD6LOXL2
SCHEMBL25434328 0.87 ACACB (0.34) CHRM4CHRM1ABHD6LOXL2DGAT2
SCHEMBL29426927 0.84 CHRM4 (0.34) CHRM4CHRM1CHRM2ABHD6DGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 — — EP claimed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 — — US claimed
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 — — US claimed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 — — EP disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 — — US disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 — — US disclosed
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP CHRM4 500/4885CHRM1 469/4885CHRM2 622/4885
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP CHRM4 516/4885CHRM1 510/4885CHRM2 682/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP CHRM4 516/4885CHRM1 510/4885CHRM2 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback